Results 221 to 230 of about 2,753,720 (285)

Tailored Porous Bimetallic Nanozyme Platform for Full‐Cycle Therapeutics of Intestinal Ischemia/Reperfusion

open access: yesAdvanced Science, EarlyView.
ABSTRACT Intestinal ischemia/reperfusion (I/R) injury presents a biphasic pathology: an acute oxidative‐inflammatory phase leading to organ failure, and a recovery phase marked by mucosal dysfunction and bacterial translocation. The developed MPB@TA‐Cu‐Ma nanocomposite functions as a dual‐phase therapeutic platform with significant efficacy. It rapidly
Chenghao Qiu   +15 more
wiley   +1 more source

Piperazine‐Functionalized Nanoparticles Enable Oral Insulin Delivery in Obese Mice

open access: yesAdvanced Science, EarlyView.
ABSTRACT Biologics have gained prominence as a rapidly advancing therapeutic modality for a diverse spectrum of medical conditions. Nonetheless, they are predominantly administered parenterally due to poor absorption through the gastrointestinal tract. Additionally, repeated injections of biologics such as insulin cause injection pain, leading to dose ...
Yuxue Cao   +14 more
wiley   +1 more source

Enzymatic DNA Reaction Networks for Orchestrating Stimuli‐Dependent Temporal Molecular Pulse

open access: yesAdvanced Science, EarlyView.
We present an enzymatic DNA reaction network (EDRN) that encodes nucleic‐acid targets in time, converting inputs into a universal strand and then into programmable transient fluorescence pulses. With time‐color multiplexing, EDRN enables single‐tube high‐plex nucleic acid detection and shows strong agreement with clinical sequencing across 32 specimens.
Jiayu Yang   +7 more
wiley   +1 more source

Wetting and Interaction of Titanium Melt with Calcium Titanate. [PDF]

open access: yesMaterials (Basel)
Mamaeva A   +6 more
europepmc   +1 more source

First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria

open access: yesAdvanced Science, EarlyView.
We report the first PROTACs designed to degrade progerin, introducing a novel therapeutic approach for progeria. The best compound, UCM‐18142, significantly reduces progerin levels and improves key disease phenotypes in patient‐derived cells and in the LmnaG609G/G609G mouse model, paving the way for new treatment strategies targeting the root cause of ...
Jon Macicior‐Michelena   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy